

Terry H Landowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10850147/publications.pdf>

Version: 2024-02-01

32
papers

8,120
citations

361413

20
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

16980
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. <i>Immunity</i> , 1999, 10, 105-115.	14.3	1,512
3	Mutations in the Fas Antigen in Patients With Multiple Myeloma. <i>Blood</i> , 1997, 90, 4266-4270.	1.4	209
4	Mitochondrial-Mediated Disregulation of Ca ²⁺ Is a Critical Determinant of Velcade (PS-341/Bortezomib) Cytotoxicity in Myeloma Cell Lines. <i>Cancer Research</i> , 2005, 65, 3828-3836.	0.9	193
5	Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. <i>Oncogene</i> , 2003, 22, 7396-7402.	5.9	180
6	Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF- κ B (RelB/p50) in myeloma cells. <i>Oncogene</i> , 2003, 22, 2417-2421.	5.9	178
7	Selection for Drug Resistance Results in Resistance to Fas-Mediated Apoptosis. <i>Blood</i> , 1997, 89, 1854-1861.	1.4	159
8	Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+ Large Granular Lymphocyte Leukemia. <i>Blood</i> , 1998, 92, 4771-4777.	1.4	148
9	Inhibition of Bcr κ Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. <i>Oncogene</i> , 2002, 21, 8804-8816.	5.9	127
10	Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines. <i>Journal of Immunology</i> , 2002, 168, 2544-2553.	0.8	109
11	Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6 κ independent mechanism. <i>Blood</i> , 2002, 100, 3333-3343.	1.4	96
12	The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. <i>Current Opinion in Oncology</i> , 2000, 12, 557-563.	2.4	86
13	Myeloma Cells Selected for Resistance to CD95-Mediated Apoptosis Are Not Cross-Resistant to Cytotoxic Drugs: Evidence for Independent Mechanisms of Caspase Activation. <i>Blood</i> , 1999, 94, 265-274.	1.4	56
14	Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. <i>Cancer Biology and Therapy</i> , 2015, 16, 43-51.	3.4	50
15	Targeting Integrin α 6 Stimulates Curative-Type Bone Metastasis Lesions in a Xenograft Model. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1558-1566.	4.1	36
16	Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2014, 124, 1259-1265.	1.4	34
17	Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1567-1576.	2.3	31
18	CD95 Antigen Mutations in Hematopoietic Malignancies. <i>Leukemia and Lymphoma</i> , 2001, 42, 835-846.	1.3	27

#	ARTICLE	IF	CITATIONS
19	Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells. <i>Molecular Cancer Research</i> , 2012, 10, 392-400.	3.4	25
20	Induction of Apoptosis and Cell Cycle Arrest by Imexon in Human Pancreatic Cancer Cell Lines. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 36, 015-028.	0.4	22
21	Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. <i>Anti-Cancer Drugs</i> , 2002, 13, 1031-1042.	1.4	21
22	Ethonafide-Induced Cytotoxicity Is Mediated by Topoisomerase II Inhibition in Prostate Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 1109-1117.	2.5	18
23	Proteasomal inhibition stabilizes topoisomerase II α protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). <i>Biochemical Pharmacology</i> , 2008, 75, 883-890.	4.4	16
24	Correlates of imexon sensitivity in human multiple myeloma cell lines. <i>Leukemia and Lymphoma</i> , 2006, 47, 97-109.	1.3	15
25	Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 749-757.	2.3	15
26	The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. <i>Investigational New Drugs</i> , 2013, 31, 1616-1625.	2.6	13
27	Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1039-1049.	2.3	12
28	Inhibition of protein synthesis by imexon reduces HIF-1 α expression in normoxic and hypoxic pancreatic cancer cells. <i>Investigational New Drugs</i> , 2009, 27, 89-98.	2.6	11
29	Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. <i>Translational Oncology</i> , 2016, 9, 228-235.	3.7	10
30	Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 183-192.	2.3	7
31	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 3047-3060.	1.4	3
32	New Therapeutic Approaches to Myeloma. , 2004, , 319-353.		0